Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why

Vertex Pharmaceuticals Incorporated (VRTX) enjoys a dominant position in the cystic fibrosis (CF) market. In the first half of 2024, Vertex's CF revenues rose almost 10%, driven by the continued strong performance of Trikafta/Kaftrio, including in younger age groups. While in the near term, expansion to younger age groups should drive CF sales growth, the potential launch of Vertex's fifth CFTR modulator therapy, vanzacaftor triple combination, should drive growth in the medium term. While CF remains the ma ...